Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298 is registered in ClinicalTrials.gov with Mercy Center for Corrective Eye Surgery as lead sponsor.

NCT NCT01325298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia
Lead sponsor
Mercy Center for Corrective Eye Surgery
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2011
Completion date
May 31, 2014
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corneal ectasia, ectasia, keratoconus